The Fauci emails: What did Tony tell Trump about Wuhan funding? Insights from the Wall Street Journal
The State-driven coronavirus narrative is unravelling. Rapidly. Yesterday, thousands of emails written by and to Dr Anthony Fauci, medical advisor to the US president, were put into the public domain. They strip the veneer from a carefully managed message. One which was mostly supported by mainstream and social media through self- and direct censorship. Ironically, some 3 200 Fauci emails, now available for anyone to download, have been exposed primarily through the legal efforts of two titles which were among the strongest propagators of the official message. For context, here’s this morning’s “Best of The Web” column from the Wall Street Journal. – Alec Hogg
Transcript: Diabetes in America Washington Post Live MS. CUNNINGHAM: Welcome to Washington Post Live. I’m Paige Winfield Cunningham, author of the Health 202 Newsletter here at The Post, and a health policy reporter. And today, we re talking about diabetes in America. And for my first guest, I would like to welcome Dr. Rita Kalyani. She s associate professor of medicine at Johns Hopkins University. Welcome to Washington Post Live, Dr. Kalyani. DR. KALYANI: Thanks so much, Paige. I m glad to be here. MS. WINFIELD CUNNINGHAM: I m looking forward to our conversation because, of course, this is a hugely important topic. You know, every time we talk about chronic health conditions, massive health spending in the U.S., diabetes is a central part of this.
The Health 202: Whether to waive coronavirus vaccine patents will be front and center this week Alexandra Ellerbeck
with Paige Winfield Cunningham The United States is under heavy pressure to help suspend intellectual property rights for coronavirus vaccines.
It ll be a hot topic as the World Trade Organization holds its general meeting this Wednesday. A temporary patent waiver on the vaccines would let more companies produce them. The U.S. has joined several other wealthy countries in blocking a proposal spearheaded by South Africa and India for a temporary patent waiver on the vaccines. The waiver would allow companies around the world to produce generic versions of coronavirus vaccines and therapeutics for a temporary time without having to worry about being sued for intellectual property violations.